Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
The Ras Gene02:38

The Ras Gene

7.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chaperone-mediated autophagy is a tumor-suppressive mechanism in hepatocellular carcinoma.

Cell reports·2026
Same author

NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.

Hepatology (Baltimore, Md.)·2026
Same author

Demonstration of SLU7 as a new cancer target.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Tumor Genotype Dictates Mitochondrial and Immune Vulnerabilities in Liver Cancer.

bioRxiv : the preprint server for biology·2025
Same author

New Experimental Mouse Models to Evaluate the Role of Transforming Growth Factor-Beta in Liver Tumorigenesis.

Liver international : official journal of the International Association for the Study of the Liver·2025

Related Experiment Video

Updated: Mar 16, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Zoi Karoulia1, Yang Wu2, Tamer A Ahmed1

  • 1Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Cancer Cell
|August 16, 2016
PubMed
Summary

RAF inhibitors combat cancer through two allosteric mechanisms, influencing drug effectiveness and resistance. Novel therapies targeting these pathways show promise, especially for BRAF-mutant cancers resistant to older drugs.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

51.1K

Related Experiment Videos

Last Updated: Mar 16, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K
The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

51.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • RAF inhibitors are crucial cancer therapeutics, yet a unified model explaining their efficacy and resistance mechanisms is lacking.
  • Understanding RAF inhibitor allosteric mechanisms is key to overcoming treatment resistance.

Purpose of the Study:

  • To elucidate the distinct allosteric mechanisms by which RAF inhibitors exert their biochemical effects.
  • To establish a unified mechanistic model for RAF inhibitor action and resistance.
  • To evaluate novel therapeutic strategies targeting these mechanisms in BRAF-driven cancers.

Main Methods:

  • Biochemical assays to analyze RAF inhibitor allosteric mechanisms.
  • Investigated inhibitor-induced RAF priming and dimerization.
  • Assessed the role of the αC helix and RAF/RAS-GTP complex formation.

Main Results:

  • RAF inhibitors operate through two distinct allosteric mechanisms.
  • Drug resistance is linked to inhibitor-stabilized αC helix position, while priming and dimerization depend on RAF/RAS-GTP complex formation.
  • The cellular effect of RAF inhibitors is a combination of these two mechanisms.

Conclusions:

  • A unified mechanistic model for RAF inhibitor action reveals two key allosteric pathways.
  • Therapeutic strategies, including αC-helix-IN inhibitors, demonstrate enhanced efficacy in BRAF-mutant colorectal and thyroid cancers.
  • These findings offer new avenues for treating cancers resistant to first-generation RAF inhibitors.